ImmunoArt is under clinical development by Educell and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ImmunoArt’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ImmunoArt overview
ImmunoArt is under development for the treatment of coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and acute graft versus host disease (aGvHD). It is administered through intravenous route. The drug candidate comprises of ex-vivo cultured allogeneic, bone-marrow derived mesenchymal stem cells.
Educell overview
Educell is a biotechnology company which develops mesenchymal stromal/stem cell (MSC) based therapies for the treatment of multiple hematological, gastroenterological, urological and orthopedic diseases; and cancer. The company’s products include ChondroArt MSC, AdipoArt and dentalArt kits. Its ImmunoArt technology platform for the preparation of cell therapy products to treat acute steroid-refractory graft versus host disease (aGvHD), a condition associated with bone marrow transplantation; CrohnArt, a cell therapy technology for developing products targeting Crohn’s disease; ChondroART 1D and ChondroART 2D technology platform for regeneration of articular cartilage; and UroART technology platform to treat high grades of vesicoureteral reflux. Educell is headquartered in Trzin, Slovenia.
For a complete picture of ImmunoArt’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
